Cellectis Financials

CLLS

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Cellectis (CLLS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLLS FY2025 2026-04-22

Cash runway, not revenue growth, is the governing mechanic here because sales swings have not made operations self-funding.

Revenue improved in FY2025, but operating cash flow swung from $23.0M in FY2024 to -$39.4M. Cash simultaneously dropped to $61.5M from $143.3M, a cash-conversion break implying the revenue line is still episodic and the business can report higher sales while becoming materially less liquid.

The balance sheet is less debt-driven than loss-driven: long-term debt fell from $71.5M in FY2021 to $27.7M in FY2025, even as equity shrank. That points to net worth erosion from recurring losses rather than weakening caused mainly by lenders adding leverage.

Short-term coverage remains intact, but the cash cushion has thinned to $61.5M against $145.8M of current liabilities. In FY2021, cash alone exceeded current liabilities, so liquidity now rests less on cash and more on the broader working-capital base, a meaningful change in how near-term obligations are covered.

Financial Health Signals

Financial Profile 37/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Cellectis's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

100

Cellectis's revenue surged 75.8% year-over-year to $72.9M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Cellectis carries a low D/E ratio of 0.37, meaning only $0.37 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Cellectis's current ratio of 1.62 is below the typical benchmark, resulting in a score of 28/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

While Cellectis generated -$39.4M in operating cash flow, capex of $2.4M consumed most of it, leaving -$41.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Cellectis generates a -89.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -28.1% the prior year.

Piotroski F-Score Weak

3/9

Cellectis passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.58x

For every $1 of reported earnings, Cellectis generates $0.58 in operating cash flow (-$39.4M OCF vs -$67.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$72.9M

YoY+75.8%

5Y CAGR+7.4%

10Y CAGR+2.7%

Cellectis generated $72.9M in revenue in fiscal year 2025. This represents an increase of 75.8% from the prior year.

EBITDA

N/A

Net Income

-$67.6M

YoY-83.9%

Cellectis reported -$67.6M in net income in fiscal year 2025. This represents a decrease of 83.9% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$41.8M

YoY-304.7%

Cellectis generated -$41.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 304.7% from the prior year.

Cash & Debt

$61.5M

YoY-57.0%

5Y CAGR-23.9%

10Y CAGR-15.8%

Cellectis held $61.5M in cash against $27.7M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

-92.7%

YoY-4.1pp

5Y CAGR+98.3pp

10Y CAGR-52.2pp

Cellectis's net profit margin was -92.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4.1 percentage points from the prior year.

Return on Equity

-89.0%

YoY-61.0pp

5Y CAGR-57.5pp

10Y CAGR-81.1pp

Cellectis's ROE was -89.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 61.0 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$2.4M

YoY-8.6%

5Y CAGR-44.3%

10Y CAGR-5.9%

Cellectis invested $2.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 8.6% from the prior year.

CLLS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$72.9M+75.8%	$41.5M+5397.4%	$755K-96.1%	$19.2M-36.8%	$30.3M-40.6%	$51.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$2.2M-15.6%	$2.6M-13.9%	$3.1M-10.4%	$3.4M-10.2%	$3.8M+62.9%	$2.3M
Income Tax	-$423K	$0-100.0%	$371K+326.4%	$87K	$0	$0
Net Income	-$67.6M-83.9%	-$36.8M+66.1%	-$108.4M+4.9%	-$114.0M+8.9%	-$125.1M-28.3%	-$97.5M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q3'23	Q2'23	Q4'22
Revenue	N/A	$16.7M	N/A	$8.1M	N/A	N/A	$178K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	$556K	N/A	$663K	N/A	N/A	$774K	N/A
Income Tax	N/A	$0	N/A	-$193K	N/A	N/A	$258K	N/A
Net Income	N/A	-$23.7M	N/A	-$25.3M	N/A	N/A	-$16.6M	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CLLS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$324.7M-15.3%	$383.5M+14.7%	$334.3M+28.0%	$261.2M-31.6%	$382.1M-18.6%	$469.5M
Current Assets	$236.2M-17.7%	$287.1M+23.2%	$233.0M+90.9%	$122.0M-45.9%	$225.4M-28.5%	$315.4M
Cash & Equivalents	$61.5M-57.0%	$143.3M+4.8%	$136.7M+46.7%	$93.2M-49.8%	$185.6M-23.0%	$241.1M
Inventory	N/A	N/A	N/A	$0	$0-100.0%	$1.6M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$535K-52.1%	$1.1M+66.3%	$671K-6.5%	$718K-61.3%	$1.9M+17.0%	$1.6M
Total Liabilities	$248.8M-1.5%	$252.5M+1.2%	$249.6M+84.5%	$135.3M-7.1%	$145.6M-9.4%	$160.6M
Current Liabilities	$145.8M-12.3%	$166.3M+7.2%	$155.1M+222.3%	$48.1M-2.5%	$49.3M-5.1%	$52.0M
Long-Term Debt	$27.7M-19.0%	$34.2M-20.3%	$42.9M-13.0%	$49.4M-31.0%	$71.5M-5.6%	$75.8M
Total Equity	$75.9M-42.1%	$131.0M+54.7%	$84.7M-32.8%	$125.9M-46.7%	$236.5M-23.4%	$308.8M
Retained Earnings	N/A	N/A	N/A	N/A	N/A	-$506.0M

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q3'23	Q2'23	Q4'22
Total Assets	$324.7M-8.3%	$354.0M-7.7%	$383.5M-5.8%	$407.1M+21.8%	$334.3M+59.4%	$209.7M-7.9%	$227.7M-12.8%	$261.2M
Current Assets	$236.2M+2.4%	$230.6M-19.7%	$287.1M-6.1%	$305.8M+31.2%	$233.0M+141.5%	$96.5M-14.8%	$113.3M-7.2%	$122.0M
Cash & Equivalents	$61.5M+2.9%	$59.8M-58.2%	$143.3M-3.9%	$149.0M+9.0%	$136.7M	N/A	$84.4M-9.5%	$93.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$535K	N/A	$1.1M+70.9%	$653K-2.7%	$671K	N/A	$695K-3.2%	$718K
Total Liabilities	$248.8M-3.1%	$256.9M+1.7%	$252.5M-2.3%	$258.5M+3.6%	$249.6M+86.8%	$133.6M+1.9%	$131.1M-3.1%	$135.3M
Current Liabilities	$145.8M-12.9%	$167.4M+0.7%	$166.3M+4.2%	$159.6M+2.9%	$155.1M+253.0%	$44.0M+4.5%	$42.0M-12.6%	$48.1M
Long-Term Debt	$27.7M-14.1%	$32.3M-5.8%	$34.2M-10.7%	$38.4M-10.7%	$42.9M	N/A	$46.2M-6.5%	$49.4M
Total Equity	$75.9M-21.8%	$97.1M-25.9%	$131.0M-11.8%	$148.6M+75.5%	$84.7M+11.3%	$76.1M-21.2%	$96.6M-23.3%	$125.9M
Retained Earnings	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CLLS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$39.4M-271.4%	$23.0M+192.9%	-$24.7M+71.7%	-$87.4M+16.4%	-$104.6M-30.3%	-$80.3M
Capital Expenditures	$2.4M-8.6%	$2.6M+140.7%	$1.1M-55.9%	$2.4M-86.9%	$18.5M-57.9%	$44.1M
Free Cash Flow	-$41.8M-304.7%	$20.4M+179.0%	-$25.8M+71.3%	-$89.9M+27.0%	-$123.1M+1.0%	-$124.3M
Investing Cash Flow	-$29.5M+71.3%	-$102.8M-562.8%	-$15.5M-461.8%	-$2.8M-137.9%	$7.3M+113.4%	-$54.3M
Financing Cash Flow	-$16.8M-118.8%	$89.1M+7.5%	$82.9M+7137.1%	$1.1M-97.6%	$47.5M+74.0%	$27.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q3'23	Q2'23	Q4'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CLLS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-92.7%-4.1pp	-88.6%+14274.7pp	-14363.3%-13768.5pp	-594.8%-182.6pp	-412.2%-221.3pp	-190.9%
Return on Equity	-89.0%-61.0pp	-28.1%+100.0pp	-128.0%-37.5pp	-90.5%-37.6pp	-52.9%-21.4pp	-31.6%
Return on Assets	-20.8%-11.2pp	-9.6%+22.9pp	-32.4%+11.2pp	-43.7%-10.9pp	-32.7%-12.0pp	-20.8%
Current Ratio	1.62-0.1	1.73+0.2	1.50-1.0	2.54-2.0	4.57-1.5	6.06
Debt-to-Equity	0.37+0.1	0.26-0.2	0.51+0.1	0.39+0.1	0.30+0.1	0.25
FCF Margin	-57.3%-106.4pp	49.2%+3468.9pp	-3419.7%-2950.9pp	-468.8%-63.1pp	-405.7%-162.1pp	-243.5%

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q3'23	Q2'23	Q4'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	-141.9%	N/A	-313.5%	N/A	N/A	-9348.9%	N/A
Return on Equity	N/A	-24.4%	N/A	-17.0%	N/A	N/A	-17.2%	N/A
Return on Assets	N/A	-6.7%	N/A	-6.2%	N/A	N/A	-7.3%	N/A
Current Ratio	1.62+0.2	1.38-0.3	1.73-0.2	1.92+0.4	1.50-0.7	2.20-0.5	2.69+0.2	2.54
Debt-to-Equity	0.37+0.0	0.33+0.1	0.260.0	0.26-0.2	0.51-1.2	1.75+1.3	0.48+0.1	0.39
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

enGene Therapeutics Inc ENGN

$545.3M

4D Molecular Therapeutics Inc. FDMT

$490.6M

Korro Bio, Inc. KRRO

$196.1M

Monte Rosa Therapeutics, Inc. GLUE

$1.6B

Abeona Therapeut ABEO

$314.9M

Frequently Asked Questions

What is Cellectis's annual revenue?

Cellectis (CLLS) reported $72.9M in total revenue for fiscal year 2025. This represents a 75.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cellectis's revenue growing?

Cellectis (CLLS) revenue grew by 75.8% year-over-year, from $41.5M to $72.9M in fiscal year 2025.

Is Cellectis profitable?

No, Cellectis (CLLS) reported a net income of -$67.6M in fiscal year 2025, with a net profit margin of -92.7%.

How much debt does Cellectis have?

As of fiscal year 2025, Cellectis (CLLS) had $61.5M in cash and equivalents against $27.7M in long-term debt.

What is Cellectis's net profit margin?

Cellectis (CLLS) had a net profit margin of -92.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Cellectis's return on equity (ROE)?

Cellectis (CLLS) has a return on equity of -89.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cellectis's free cash flow?

Cellectis (CLLS) generated -$41.8M in free cash flow during fiscal year 2025. This represents a -304.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cellectis's operating cash flow?

Cellectis (CLLS) generated -$39.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cellectis's total assets?

Cellectis (CLLS) had $324.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cellectis's capital expenditures?

Cellectis (CLLS) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

What is Cellectis's current ratio?

Cellectis (CLLS) had a current ratio of 1.62 as of fiscal year 2025, which is generally considered healthy.

What is Cellectis's debt-to-equity ratio?

Cellectis (CLLS) had a debt-to-equity ratio of 0.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cellectis's return on assets (ROA)?

Cellectis (CLLS) had a return on assets of -20.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cellectis's cash runway?

Based on fiscal year 2025 data, Cellectis (CLLS) had $61.5M in cash against an annual operating cash burn of $39.4M. This gives an estimated cash runway of approximately 19 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Cellectis's Piotroski F-Score?

Cellectis (CLLS) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cellectis's earnings high quality?

Cellectis (CLLS) has an earnings quality ratio of 0.58x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Cellectis?

Cellectis (CLLS) scores 37 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.